Kişi:
DEMİRDÖĞEN, EZGİ

Profil Resmi

E-posta Adresi

Doğum Tarihi

Durumu

Araştırma Projeleri

Akademik Birimler

OrgUnit Logosu
Akademik Birim

Ünvanı

person.page.name

Ad

EZGİ

Soyad

DEMİRDÖĞEN

Filtreler

20212
Filtreleri Sıfırla

Ayarlar

Konu: Covid-19 ×

Arama Sonuçları

Şimdi gösteriliyor 1 - 2 / 2
  • Küçük resim yok
    YayınSadece Metadata
    Interleukin-21: A potential biomarker for diagnosis and predicting prognosis in covid-19 patients
    (Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Acet Ozturk, Nilufer Aylin; ACET ÖZTÜRK, NİLÜFER AYLİN; Ursavas, Ahmet; URSAVAŞ, AHMET; Gorek Dilektasli, Asli; GÖREK DİLEKTAŞLI, ASLI; Demirdogen, Ezgi; DEMİRDÖĞEN, EZGİ; Coskun, Necmiye Funda; COŞKUN, NECMİYE FUNDA; Ediger, Dane; EDİGER, DANE; Uzaslan, Ayse Esra; UZASLAN, AYŞE ESRA; Yoyen-Ermis, Digdem; YÖYEN ERMİŞ, DİĞDEM; Karaca, Mert; KARACA, MERT; Terzi, Orkun Eray; TERZİ, ORKUN ERAY; Bayram, Merve; BAYRAM, MERVE; Omer Topcu, Dilara; ÖMER TOPÇU, DİLARA; Yigitliler, Busra; Yurttas, Ahmet; YURTTAŞ, AHMET; Maharramov, Shahriyar; Yazici, Gamze; YAZICI, GAMZE; Oral, Haluk Barbaros; ORAL, HALUK BARBAROS; Karadag, Mehmet; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-2954-4293; 0000-0001-5871-8769; 0000-0003-0463-6818; 0000-0002-9027-1132; AAG-7406-2021; AAD-1271-2019; AAH-3888-2021; K-7285-2012; AAG-8744-2021; AAI-3169-2021; JPK-7012-2023; AAE-9142-2019
    Background/aim: COVID-19 patients have a wide spectrum of disease severity. Several biomarkers were evaluated as predictors for progression towards severe disease. IL-21 is a member of common gamma-chain cytokine family and creates some specific effects during programming and maintenance of antiviral immunity. We aimed to assess IL-21 as a biomarker for diagnosis and outcome prediction in patients hospitalized with COVID-19. Materials and methods: Patients with a preliminary diagnosis of COVID-19 and pneumonia other than COVID-19 admitted to a tertiary care hospital were included consecutively in this comparative study. Results: The study population consisted of 51 patients with COVID-19 and 11 patients with non-COVID-19 pneumonia. Serum IL-21 concentration was markedly higher, and serum CRP concentration was significantly lower in COVID-19 patients compared to nonCOVID-19 pneumonia patients. Within COVID-19 patients, 10 patients showed radiological and clinical progression. Patients with clinical worsening had lower lymphocyte count and haemoglobin. In addition to that, deteriorating patients had higher urea, LDH levels, and elevated concentration of both IL-6 and IL-21. The cut-off value of 106 ng/L for IL-21 has 80.0% sensitivity, %60.9 specificity for discriminating patients with clinical worsening. Multivariable analysis performed to define risk factors for disease progression identified IL-6 and IL-21 as independent predictors. Odds ratio for serum IL-6 concentrations >_ 3.2 pg/mL was 8.07 (95% CI: 1.3747.50, p = 0.04) and odds ratio for serum IL-21 concentrations >_ 106 ng/L was 6.24 (95% CI: 1.04 - 37.3, p = 0.02). Conclusion: We identified specific differences in serum IL-21 between COVID-19 and non-COVID-19 pneumonia patients. Serum IL-21 measurement has promising predictive value for disease progression in COVID-19 patients. High serum IL-6 and IL-21 levels obtained upon admission are independent risk factors for clinical worsening.
  • Küçük resim yok
    YayınSadece Metadata
    Impact of covid-19 pneumonia on pulmonary function, functional exercise capacity and quality of life
    (European Respiratory Soc Journals, 2021-09-05) Dilektasli, Asli Gorek; GÖREK DİLEKTAŞLI, ASLI; Ozturk, Nilufer; ACET ÖZTÜRK, NİLÜFER AYLİN; Odabas, Ayten; Demirdogen, Ezgi; DEMİRDÖĞEN, EZGİ; Ursavas, Ahmet; URSAVAŞ, AHMET; Coskun, Funda; COŞKUN, NECMİYE FUNDA; Guclu, Ozge Aydin; AYDIN GÜÇLÜ, ÖZGE; Ediger, Dane; EDİGER, DANE; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0003-1005-3205; 0000-0002-2954-4293; AAI-3169-2021; AAE-9142-2019; JPK-7012-2023; AAD-1271-2019